NeuroMetrix Inc Asset Resilience Ratio
NeuroMetrix Inc asset resilience ratio. NeuroMetrix Inc (NURO) has an Asset Resilience Ratio of 76.14% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of NeuroMetrix Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NeuroMetrix Inc (2004–2024)
Asset resilience ratio of NeuroMetrix Inc from 2004 to 2024. This chart shows how NeuroMetrix Inc's Asset Resilience Ratio has changed over time. Read how much debt does NeuroMetrix Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NeuroMetrix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is NeuroMetrix Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.67 Million | 76.14% |
| Total Liquid Assets | $11.67 Million | 76.14% |
Asset Resilience Insights
- Very High Liquidity: NeuroMetrix Inc maintains exceptional liquid asset reserves at 76.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NeuroMetrix Inc Industry Peers by Asset Resilience Ratio
Compare NeuroMetrix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
NeuroMetrix Inc Asset Resilience Ratio by Year (2004–2024)
NeuroMetrix Inc asset resilience ratio by year from 2004 to 2024. The table below shows the annual Asset Resilience Ratio data for NeuroMetrix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 76.14% | $11.67 Million | $15.32 Million | +0.22pp |
| 2023-12-31 | 75.92% | $16.27 Million | $21.42 Million | +7.23pp |
| 2022-12-31 | 68.69% | $16.95 Million | $24.67 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $24.89 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $9.60 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.28 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $16.03 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.40 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $10.80 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $10.88 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $14.22 Million | -- |
| 2009-12-31 | 18.48% | $7.50 Million | $40.57 Million | -5.41pp |
| 2008-12-31 | 23.89% | $7.50 Million | $31.38 Million | -16.24pp |
| 2007-12-31 | 40.13% | $22.62 Million | $56.37 Million | -18.05pp |
| 2006-12-31 | 58.18% | $32.41 Million | $55.71 Million | +2.04pp |
| 2005-12-31 | 56.14% | $24.08 Million | $42.90 Million | +7.20pp |
| 2004-12-31 | 48.94% | $18.57 Million | $37.95 Million | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more